Table 2.
Results of the univariate analysis for patients with cervical cancer treated with pelvic irradiation
| Characteristic | 3-year PALNF rate | P value |
|---|---|---|
| Age (years) | ||
| < 65 | 3.8% | 0.501 |
| ≥ 65 | 1.6% | |
| Histology | ||
| Squamous cell carcinoma | 3.6% | 0.922 |
| Nonsquamous cell carcinoma | 3.2% | |
| 2018 FIGO stage | ||
| IB3-IIIA | 1.7% | <0.001 |
| IIIB | 9.5% | |
| IIIC1 | 11.3% | |
| Primary tumor size | ||
| < 4 cm | 1.8% | 0.108 |
| ≥ 4 cm | 4.8% | |
| Tumor extension to the pelvic wall | ||
| Yes | 12.8% | 0.015 |
| No | 3.0% | |
| Common iliac MLNs | ||
| Yes | 3.4% | 0.026 |
| No | 20.0% | |
| Number of pelvic MLNs | ||
| 0 | 2.2% | 0.001 |
| 1 | 8.8% | |
| ≥2 | 14.9% | |
| Large pelvic MLNs (≥ 1.5 cm) | ||
| Yes | 11.2% | 0.245 |
| No | 3.3% | |
| Concurrent chemotherapy | ||
| Yes | 3.8% | 0.674 |
| No | 2.4% | |
Abbreviations: MLNs = metastatic lymph nodes.